Today we are going to purchase puts/Short AVNR: The below article shows how this is only a phase two result and there are two more phases this drug has to go through...I love these because these are easy money.

8:31 am Avanir Pharmaceuticals announces positive Phase II trial results for AVP-923 in treatment of agitation in patients with Alzheimer's disease (AVNR) :

• Co announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
• Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression domain score of the neuropsychiatric inventory (NPI) compared to placebo (p=0.00008).
• The reduction in agitation was observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design.
• Significantly Improved Agitation in 220-Patient 10-week Study - - Co Plans to Meet with FDA to Discuss Initiation of Pivotal Development Program.
•